A Chlamydomonas-Derived Human Papillomavirus 16 E7 Vaccine Induces Specific Tumor Protection

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Demurtas, Olivia C ^a   Massa, Silvia ^a   Ferrante, Paola ^a   Venuti, Aldo ^b   Franconi, Rosella ^a   Giuliano, Giovanni ^a  

^a ENEA C R CASACCIA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALGAL EXTRACT; CHLAMYDOMONAS EXTRACT; E7GGG PROTEIN; HUMAN PAPILLOMAVIRUS 16 E7 VACCINE; IMMUNOGLOBULIN G ANTIBODY; PROTEIN E7; UNCLASSIFIED DRUG; WART VIRUS VACCINE; 3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; HYBRID PROTEIN; SUBUNIT VACCINE; VIRUS ANTIBODY;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER PREVENTION; CARCINOGENESIS; CHLAMYDOMONAS REINHARDTII; CHLOROPLAST; CHLOROPLAST GENOME; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; E7GGG GENE; FEMALE; GENE EXPRESSION; HOMOLOGOUS RECOMBINATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR IMMUNITY; UTERINE CERVIX CANCER; VIRUS ONCOGENE; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGY; MORTALITY; PAPILLOMAVIRUS INFECTIONS; SURVIVAL; UTERINE CERVICAL NEOPLASMS;

CHLAMYDOMONAS; CHLAMYDOMONAS REINHARDTII; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

3' UNTRANSLATED REGIONS; 5' UNTRANSLATED REGIONS; ANIMALS; ANTIBODIES, VIRAL; CELL LINE, TUMOR; CHLAMYDOMONAS REINHARDTII; CHLOROPLASTS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS; VACCINES, SUBUNIT;

EID: 84876587491     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061473     Document Type: Article

References (47)

1. Yusibov V, Streatfield SJ, Kushnir N, (2011) Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum Vaccin 7 (3):: 313-321.
2. Paul M, Ma JK, (2011) Plant-made pharmaceuticals: leading products and production platforms. Biotechnol Appl Biochem 58 (1):: 58-67.
3. Twyman RM, Schillberg S, Fischer R (2012) The Production of Vaccines and Therapeutic Antibodies in Plants. In: Ma S, Wang A (eds) Molecular Farming in Plants: Recent Advances and Future Prospects.Springer, NY: 145-159.
4. Franconi R, Demurtas OC, Massa S, (2010) Plant-derived vaccines and other therapeutics produced in contained systems. Expert Rev Vaccines 9 (8):: 877-892.
5. Fox JL, (2012) First plant-made biologic approved. Nat Biotechnol 30 (6):: 472.
6. Merchant SS, Prochnik SE, Vallon O, Harris EH, Karpowicz SJ, et al. (2007) The Chlamydomonas genome reveals the evolution of key animal and plant functions. Science 318: 245-251.
7. Walker TL, Purton S, Becker DK, Collet C, (2005) Microalgae as bioreactors. Plant Cell Rep 24: 629-641.
8. Specht E, Miyake-Stoner S, Mayfield S, (2010) Micro-algae come of age as a platform for recombinant protein production. Biotechnol Lett 32 (10):: 1373-1383.
9. Debuchy R, Purton S, Rochaix JD, (1989) The argininosuccinate lyase gene of Chlamydomonas reinhardtii: An important tool for nuclear transformation and for correlating the genetic and molecular maps of the ARG7 locus. EMBO J 8: 2803-2809.
10. Schroda M, (2006) RNA silencing in Chlamydomonas: mechanisms and tools. Curr Genet 49 (2):: 69-84.
11. Mayfield SP, Manuell AL, Chen S, Wu J, Tran M, et al. (2007) Chlamydomonas reinhardtii chloroplasts as protein factories. Curr Opin Biotechnol 18: 126-133.
12. Rasala BA, Mayfield SP, (2011) The microalga Chlamydomonas reinhardtii as a platform for the production of human protein therapeutics. Bioeng Bugs 2 (1):: 50-54.
13. Sun M, Qian K, Su N, Chang H, Liu J, et al. (2003) Foot-and-mouth disease virus VP1 protein fused with cholera toxin B subunit expressed in Chlamydomonas reinhardtii chloroplast. Biotechnol Lett 25 (13):: 1087-1092.
14. Dreesen IAJ, Hamri GCE, Fusseneggera M, (2010) Heat-stable oral alga-based vaccine protects mice from Staphylococcus aureus infection. J Biotechnol 145: 273-280.
15. Gregory JA, Li F, Tomosada LM, Cox CJ, Topol AB, et al. (2012) Algae-produced pfs25 elicits antibodies that inhibit malaria transmission. PLoS One 7 (5):: e37179.
16. Mayfield SP, Franklin SE, Lerner RA, (2003) Expression and assembly of a fully active antibody in algae. Proc Natl Acad Sci U S A 100 (2):: 438-442.
17. Tran M, Zhou B, Pettersson PL, Gonzalez MJ, Mayfield SP, (2009) Synthesis and assembly of a full-length human monoclonal antibody in algal chloroplasts. Biotechnol Bioeng 104 (4):: 633-673.
18. Rasala BA, Muto M, Lee PA, Jager M, Cardoso RM, et al. (2010) Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of Chlamydomonas reinhardtii. Plant Biotechnol J 8 (6):: 719-733.
19. Li SS, Tsai HJ, (2009) Transgenic microalgae as a non-antibiotic bactericide producer to defend against bacterial pathogen infection in the fish digestive tract. Fish Shellfish Immunol 26: 316-325.
20. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM, (2010) The global burden of cancer: priorities for prevention. Carcinogenesis 31 (1):: 100-110.
21. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19.
22. Da Silva DM, Eiben GL, Fausch SC, Wakabayashi MT, Rudolf MP, et al. (2001) Cervical cancer vaccines: emerging concepts and developments. J Cell Physiol 186: 169-182.
23. McLaughlin-Drubin ME, Münger K, (2009) The human papillomavirus E7 oncoprotein. Virology 384: 335-344.
24. Su JH, Wu A, Scotney E, Ma B, Monie A, et al. (2010) Immunotherapy for Cervical Cancer: Research Status and Clinical Potential. BioDrugs 24 (2):: 109-129.
25. Giorgi C, Franconi F, Ribicki EP, (2010) Human papillomavirus vaccines in plant. Expert Rev Vaccines 9 (8):: 913-924.
26. Massa S, Franconi R, Brandi R, Muller A, Mett V, et al. (2007) Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine 25: 3018-3021.
27. Franconi R, Di Bonito P, Dibello F, Accardi L, Muller A, et al. (2002) Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res 62: 3654-3658.
28. Morgenfeld M, Segretin ME, Wirth S, Lentz E, Zelada A, et al. (2009) Potato virus X coat protein fusion to human papillomavirus 16 E7 oncoprotein enhance antigen stability and accumulation in tobacco chloroplast. Mol Biotechnol 43 (3):: 243-249.
29. Franconi R, Massa S, Illiano E, Muller A, Cirilli A, et al. (2006) Exploiting the plant secretory pathway to improve the anti-cancer activity of a plant-derived HPV16 E7 vaccine. Int J Immunopath Pharmacol 19 (1):: 187-197.
30. Venuti A, Massa S, Mett V, Vedova LD, Paolini F, et al. (2009) An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine 27: 3395-3397.
31. Smahel M, Sima P, Ludvikova V, Vonka V, (2001) Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281: 231-238.
32. Hopp TP, Prickett KS, Price VL, Libby RT, March CJ, et al. (1988) A short polypeptide marker sequence useful for recombinant protein identification and purification. Nat Biotechnol 6: 1204-1210.
33. Hochuli E, Bannwarth W, Döbeli H, Gentz R, Stüber D, (1988) Genetic Approach to Facilitate Purification of Recombinant Proteins with a Novel Metal Chelate Adsorbent. Nat Biotechnol 6 (11):: 1321-1325.
34. Surzycki R, Greenham K, Kitayama K, Dibal F, Wagner R, et al. (2009) Factors effecting expression of vaccines in microalgae. Biologicals 37 (3):: 133-138.
35. Kindle KL, Kristy T, Richards L, Stern DB, (1991) Engineering the chloroplast genome: Techniques and capabilities for chloroplast transformation in Chlamydomonas reinhardtii. Proc Natl Acad Sci U S A 88: 1721-1725.
36. Buyel JF, Bautista JA, Fischer R, Yusibov VM, (2012) Extraction, purification and characterization of the plant-produced HPV16 subunit vaccine candidate E7GGG. J Chromatogr B Analyt Technol Biomed Life Sci 880 (1):: 19-26.
37. Paz De la Rosa G, Monroy-García A, Mora-García ML, Peña CG, Hernández-Montes J, et al. (2009) An HPV 16 L1-based chimeric human papillomavirus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. Virol J 6: 1-11.
38. Futatsumori-Sugai M, Abe R, Watanabe M, Kudou M, Yamamoto T, et al. (2009) Utilization of Arg-elution method for Flag-tag based chromatography. Protein Expr Purif 67 (2):: 148-155.
39. Frazer IH, (2004) Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 4 (1):: 46-54.
40. Dunn LA, Evander M, Tindle RW, Bulloch AL, de Kluyver RL, et al. (1997) Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. Virology 235: 94-103.
41. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, et al. (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56 (1):: 21-26.
42. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, et al. (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361 (19):: 1838-1847.
43. de Vos van Steenwijk PJ, Ramwadhdoebe TH, Löwik MJ, van der Minne CE, Berends-van der Meer DM, et al. (2012) A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother 61 (9):: 1485-1492.
44. Cerutti ML, Alonso LG, Tatti S, de Prat-Gay G, (2012) Long-lasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model. Int J Cancer 130 (8):: 1813-1820.
45. Alonso LG, Garcìa-Alai MM, Nadra AD, Lape AN, Almeida FL, et al. (2002) High-risk (HPV16) human papillomavirus E7 oncoprotein is highly stable and extended, with conformational transitions that could explain its multiplecellular binding partners. Biochemistry 41 (33):: 10510-10518.
46. Smal C, Alonso LG, Wetzler DE, Heer A, de Prat Gay G, (2012) Ordered self-assembly mechanism of a spherical oncoprotein oligomer triggered by zinc removal and stabilized by an intrinsically disordered domain. PLoS One 7 (5):: e36457.
47. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, De Jongh BM, et al. (1993) Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23: 2242-2249.